{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:53:19Z","timestamp":1780717999255,"version":"3.54.1"},"update-to":[{"DOI":"10.1371\/journal.pntd.0006870","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T00:00:00Z","timestamp":1541635200000}}],"reference-count":69,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC_13073"],"award-info":[{"award-number":["MC_PC_13073"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/P017339\/1"],"award-info":[{"award-number":["MR\/P017339\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["106917\/Z\/15\/Z"],"award-info":[{"award-number":["106917\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["201477\/Z\/16\/Z"],"award-info":[{"award-number":["201477\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0006870","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T13:33:25Z","timestamp":1540820005000},"page":"e0006870","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":43,"title":["A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis"],"prefix":"10.1371","volume":"12","author":[{"given":"Chuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawan","family":"Dulal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiquan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooman","family":"Goharriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Banyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicky","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Collin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Draper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian V. S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Ashfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony R.","family":"Fooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegund C.","family":"Ertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5410-7562","authenticated-orcid":true,"given":"Alexander D.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,10,29]]},"reference":[{"issue":"7","key":"ref1","doi-asserted-by":"crossref","first-page":"e2865","DOI":"10.1371\/journal.pntd.0002865","article-title":"The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases","volume":"8","author":"PJ Hotez","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"9963","key":"ref2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age\u2013sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","year":"2015","journal-title":"The Lancet"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"e0003709","DOI":"10.1371\/journal.pntd.0003709","article-title":"Estimating the global burden of endemic canine rabies","volume":"9","author":"K Hampson","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"ref4","unstructured":"GAVI. Vaccine Investment Strategy 2013 [<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.gavi.org\/library\/gavi-documents\/strategy\/final-vis-analysis-2013\u2014rabies\/\" xlink:type=\"simple\">http:\/\/www.gavi.org\/library\/gavi-documents\/strategy\/final-vis-analysis-2013\u2014rabies\/<\/ext-link>. Accessed 01 July 2018]"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"17091","DOI":"10.1038\/nrdp.2017.91","article-title":"Rabies","volume":"3","author":"AR Fooks","year":"2017","journal-title":"Nature Reviews Disease Primers"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1371\/journal.pntd.0000626","article-title":"The feasibility of canine rabies elimination in Africa: dispelling doubts with data","volume":"4","author":"T Lembo","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"17\u201318","key":"ref7","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0264-410X(02)00778-8","article-title":"A dog rabies vaccination campaign in rural Africa: impact on the incidence of dog rabies and human dog-bite injuries","volume":"21","author":"S Cleaveland","year":"2003","journal-title":"Vaccine"},{"issue":"9","key":"ref8","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.vaccine.2005.03.059","article-title":"Cost comparison of rabies pre-exposure vaccination with post-exposure treatment in Thai children","volume":"24","author":"P Chulasugandha","year":"2006","journal-title":"Vaccine"},{"key":"ref9","unstructured":"Rabies vaccines: WHO position paper\u2014April 2018. WHO Weekly Epidemiological Record. 2018;93(16):201\u201320."},{"key":"ref10","article-title":"Pre-exposure intradermal rabies vaccination: a non-inferiority trial in healthy adults on shortening the vaccination schedule from 28 to 7 days","author":"P Soentjens","year":"2018","journal-title":"Clinical Infectious Diseases"},{"key":"ref11","unstructured":"Milstien JB, Galazka AM, Kartoglu \u00dc, Zaffran M, World Health Organization. Dept. of Immunization Vaccines and Biologicals. Temperature sensitivity of vaccines. Geneva: World Health Organization; 2006. ix, 62 p. p."},{"key":"ref12","unstructured":"PATH. Summary of Stability Data for Licensed Vaccines 2012 [<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.path.org\/publications\/files\/TS_vaccine_stability_table.pdf\" xlink:type=\"simple\">http:\/\/www.path.org\/publications\/files\/TS_vaccine_stability_table.pdf<\/ext-link>. Accessed 01 July 2018]"},{"issue":"8326 Pt 1","key":"ref13","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(83)91984-0","article-title":"Purified chicken embryo cell rabies vaccine for human use","volume":"1","author":"R Barth","year":"1983","journal-title":"Lancet"},{"issue":"46","key":"ref14","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1016\/j.vaccine.2016.10.015","article-title":"Thermotolerance of an inactivated rabies vaccine for dogs","volume":"34","author":"FJ Lankester","year":"2016","journal-title":"Vaccine"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2471\/BLT.16.173039","article-title":"Pre-exposure rabies prophylaxis: a systematic review","volume":"95","author":"JA Kessels","year":"2017","journal-title":"Bulletin of the World Health Organization"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0264-410X(92)90029-J","article-title":"Longevity of rabies antibody titre in recipients of human diploid cell rabies vaccine","volume":"10","author":"DJ Briggs","year":"1992","journal-title":"Vaccine"},{"issue":"48","key":"ref17","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1016\/j.vaccine.2016.09.058","article-title":"Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans","volume":"34","author":"KL Mansfield","year":"2016","journal-title":"Vaccine"},{"issue":"8","key":"ref18","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1517\/14712598.2012.691162","article-title":"Preventative childhood vaccination to rabies","volume":"12","author":"Q Liu","year":"2012","journal-title":"Expert opinion on biological therapy"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","article-title":"Vaccines: correlates of vaccine-induced immunity","volume":"47","author":"SA Plotkin","year":"2008","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.20506\/rst.11.3.622","article-title":"Practical significance of rabies antibodies in cats and dogs","volume":"11","author":"MF Aubert","year":"1992","journal-title":"Rev Sci Tech"},{"issue":"9","key":"ref21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2217\/fvl-2016-0070","article-title":"Simian adenoviruses as vaccine vectors","volume":"11","author":"SJ Morris","year":"2016","journal-title":"Future Virology"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/hum.2014.007","article-title":"Challenges in manufacturing adenoviral vectors for global vaccine product deployment","volume":"25","author":"J Vellinga","year":"2014","journal-title":"Hum Gene Ther"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.virol.2013.12.029","article-title":"Protection of non-human primates against rabies with an adenovirus recombinant vaccine","volume":"450\u2013451","author":"ZQ Xiang","year":"2014","journal-title":"Virology"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1128\/JVI.76.6.2667-2675.2002","article-title":"Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product","volume":"76","author":"Z Xiang","year":"2002","journal-title":"J Virol"},{"key":"ref25","unstructured":"WHO. Progress and Challenges with Achieving Universal Immunization Coverage: 2016 Estimates of Immunization Coverage 2016 [<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/entity\/immunization\/monitoring_surveillance\/who-immuniz.pdf?ua=1\" xlink:type=\"simple\">http:\/\/www.who.int\/entity\/immunization\/monitoring_surveillance\/who-immuniz.pdf?ua=1<\/ext-link>. Accessed 01 July 2018]"},{"issue":"23","key":"ref26","doi-asserted-by":"crossref","first-page":"11603","DOI":"10.1128\/JVI.75.23.11603-11613.2001","article-title":"Replication-defective vector based on a chimpanzee adenovirus","volume":"75","author":"SF Farina","year":"2001","journal-title":"J Virol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ncomms1615","article-title":"The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody","volume":"2","author":"AD Douglas","year":"2011","journal-title":"Nat Commun"},{"issue":"8","key":"ref28","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1128\/JVI.02568-07","article-title":"Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A","volume":"82","author":"S Sridhar","year":"2008","journal-title":"J Virol"},{"issue":"1","key":"ref29","first-page":"145","article-title":"Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses","volume":"78","author":"A Reyes-Sandoval","year":"2010","journal-title":"InfectImmun"},{"issue":"7","key":"ref30","doi-asserted-by":"crossref","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"MD Dicks","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jviromet.2004.08.017","article-title":"Optimized large-scale production of high titer lentivirus vector pseudotypes","volume":"122","author":"M Sena-Esteves","year":"2004","journal-title":"J Virol Methods"},{"issue":"26","key":"ref32","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1016\/j.vaccine.2008.04.007","article-title":"Genetic characterisation of attenuated SAD rabies virus strains used for oral vaccination of wildlife","volume":"26","author":"L Geue","year":"2008","journal-title":"Vaccine"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/bit.24342","article-title":"Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors","volume":"109","author":"MG Cottingham","year":"2012","journal-title":"Biotechnol Bioeng"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1093\/nar\/30.2.e9","article-title":"High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells","volume":"30","author":"Y Durocher","year":"2002","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/sj.gt.3302675","article-title":"Chimpanzee-origin adenovirus vectors as vaccine carriers","volume":"13","author":"N Tatsis","year":"2006","journal-title":"Gene Ther"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.vaccine.2012.07.074","article-title":"Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia","volume":"31","author":"R Ventura","year":"2013","journal-title":"Vaccine"},{"issue":"23","key":"ref37","first-page":"279","article-title":"Laboratory techniques in rabies: the NIH test for potency","author":"EB Seligmann Jr","year":"1973","journal-title":"Monogr Ser World Health Organ"},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0022-1759(97)00212-3","article-title":"Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody","volume":"212","author":"F Cliquet","year":"1998","journal-title":"J Immunol Methods"},{"issue":"4","key":"ref39","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0092-1157(75)90061-X","article-title":"Measurement of rabies antibody: comparison of the mouse neutralization test (MNT) with the rapid fluorescent focus inhibition test (RFFIT)","volume":"3","author":"RE Louie","year":"1975","journal-title":"J Biol Stand"},{"issue":"2","key":"ref40","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jmb.2010.07.001","article-title":"Structure and properties of a complex of alpha-synuclein and a single-domain camelid antibody","volume":"402","author":"EJ De Genst","year":"2010","journal-title":"J Mol Biol"},{"issue":"4","key":"ref41","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.4049\/jimmunol.1502472","article-title":"Germinal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines","volume":"197","author":"C Wang","year":"2016","journal-title":"J Immunol"},{"issue":"5","key":"ref42","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.4049\/jimmunol.1101004","article-title":"The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus","volume":"187","author":"SC de Cassan","year":"2011","journal-title":"J Immunol"},{"issue":"20","key":"ref43","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.vaccine.2016.03.061","article-title":"Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle","volume":"34","author":"P Dulal","year":"2016","journal-title":"Vaccine"},{"key":"ref44","unstructured":"Evans R, Volkin D, Isopi L. Adenovirus formulations. US patent number: US 7456,009 B2, 25 Nov 2008."},{"issue":"6","key":"ref45","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1128\/JVI.76.6.2667-2675.2002","article-title":"Novel, Chimpanzee Serotype 68-Based Adenoviral Vaccine Carrier for Induction of Antibodies to a Transgene Product","volume":"76","author":"Z Xiang","year":"2002","journal-title":"Journal of Virology"},{"issue":"4","key":"ref46","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"N Tatsis","year":"2004","journal-title":"Mol Ther"},{"issue":"2","key":"ref47","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1128\/JVI.71.2.1115-1123.1997","article-title":"Structural analysis of the adenovirus type 5 E1B 55-kilodalton-E4orf6 protein complex","volume":"71","author":"S Rubenwolf","year":"1997","journal-title":"J Virol"},{"issue":"Pt 8","key":"ref48","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1099\/vir.0.81956-0","article-title":"Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells","volume":"87","author":"M Havenga","year":"2006","journal-title":"J Gen Virol"},{"issue":"7\u20138","key":"ref49","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0734-9750(02)00030-7","article-title":"Production of adenovirus vector for gene therapy","volume":"20","author":"I Nadeau","year":"2003","journal-title":"Biotechnol Adv"},{"key":"ref50","unstructured":"De Cassan S, Douglas A, Draper S, Forbes E, Goodman A, Hill A, et al. Viral vector immunogenic compositions. US Patent Application, Publication number US 2014\/0127258 A1, 08 May 2014."},{"issue":"35","key":"ref51","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1016\/j.vaccine.2007.06.019","article-title":"Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant","volume":"25","author":"OJ Ophorst","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"ref52","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14760584.6.5.699","article-title":"MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection","volume":"6","author":"DT O\u2019Hagan","year":"2007","journal-title":"Expert review of vaccines"},{"issue":"19","key":"ref53","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000490","article-title":"Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass","volume":"2","author":"R Alcock","year":"2010","journal-title":"Science Translational Medicine"},{"issue":"10","key":"ref54","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/jps.20157","article-title":"Development of stable liquid formulations for adenovirus-based vaccines","volume":"93","author":"RK Evans","year":"2004","journal-title":"J Pharm Sci"},{"key":"ref55","unstructured":"Jezek J, Buckler A. Stable aqueous formulations of adenovirus vectors. US Patent number: US 9.254,332 B2, 9 Feb 2016."},{"issue":"17","key":"ref56","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.gt.3301527","article-title":"Development of formulations that enhance physical stability of viral vectors for gene therapy","volume":"8","author":"MA Croyle","year":"2001","journal-title":"Gene Ther"},{"issue":"1\u20132","key":"ref57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijpharm.2016.04.067","article-title":"Evaluation of excipients for enhanced thermal stabilization of a human type 5 adenoviral vector through spray drying","volume":"506","author":"DA LeClair","year":"2016","journal-title":"Int J Pharm"},{"issue":"27","key":"ref58","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1016\/j.vaccine.2010.04.059","article-title":"Stabilizing formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine (AERAS-402)","volume":"28","author":"TH Jin","year":"2010","journal-title":"Vaccine"},{"key":"ref59","unstructured":"Luitjens A, Lewis JA. Method for the production of adenoviral vectors. US Patent number: US 10,041,049 B2; 07 Aug 2018."},{"issue":"17","key":"ref60","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA","volume":"374","author":"K Ewer","year":"2016","journal-title":"N Engl J Med"},{"issue":"21","key":"ref61","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96381","article-title":"Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions","volume":"2","author":"RO Payne","year":"2017","journal-title":"JCI Insight"},{"issue":"4","key":"ref62","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1128\/CVI.00418-07","article-title":"Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responses","volume":"15","author":"R Geiben-Lynn","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"Pt 7","key":"ref63","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1099\/0022-1317-80-7-1647","article-title":"Soluble ectodomain of rabies virus glycoprotein expressed in eukaryotic cells folds in a monomeric conformation that is antigenically distinct from the native state of the complete, membrane-anchored glycoprotein","volume":"80","author":"Y Gaudin","year":"1999","journal-title":"J Gen Virol"},{"issue":"9","key":"ref64","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.3390\/molecules14093286","article-title":"Squalene emulsions for parenteral vaccine and drug delivery","volume":"14","author":"CB Fox","year":"2009","journal-title":"Molecules"},{"key":"ref65","unstructured":"WHO. Controlled Temperature Chain: Strategic Roadmap for Priority Vaccines 2017 [<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/immunization\/programmes_systems\/supply_chain\/ctc_strategic_roadmap_priority_vaccines.pdf\" xlink:type=\"simple\">http:\/\/www.who.int\/immunization\/programmes_systems\/supply_chain\/ctc_strategic_roadmap_priority_vaccines.pdf<\/ext-link>; accessed 01 July 2018]."},{"issue":"7","key":"ref66","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1586\/14760584.2014.923761","article-title":"Tools and approaches to ensure quality of vaccines throughout the cold chain","volume":"13","author":"U Kartoglu","year":"2014","journal-title":"Expert review of vaccines"},{"key":"ref67","unstructured":"WHO Expert Consultation on Rabies, Third Report. Geneva: World Health Organization; 2018."},{"issue":"19","key":"ref68","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1016\/j.vaccine.2011.12.028","article-title":"One clinic visit for pre-exposure rabies vaccination (a preliminary one year study)","volume":"30","author":"P Khawplod","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"ref69","article-title":"Single visit rabies pre-exposure priming induces a robust anamnestic antibody response after simulated post-exposure vaccination: results of a dose-finding study","volume":"24","author":"EFF Jonker","year":"2017","journal-title":"J Travel Med"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0006870","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T00:00:00Z","timestamp":1541635200000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0006870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T02:36:42Z","timestamp":1605321402000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0006870"}},"subtitle":[],"editor":[{"given":"Charles E","family":"Rupprecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,29]]},"references-count":69,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0006870","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/408013","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,29]]}}}